Cop17 ib lungile shoba zikhali 061211


Published on

Description of activities of the Technology Innovation Agency in Industrial Biotechnology

Published in: Technology, Business
  • Be the first to comment

  • Be the first to like this

No Downloads
Total views
On SlideShare
From Embeds
Number of Embeds
Embeds 0
No embeds

No notes for slide

Cop17 ib lungile shoba zikhali 061211

  1. 1. Industrial Biotechnologies For Climate Change COP 17 Lungile Shoba-Zikhali (GM – Industrial Biotechnology)
  2. 2. Technology Innovation Agency (TIA) TIA …A world class innovation agency that supports and enablestechnological innovation to achieve socio-economic benefits for South Africa through leveraging strategic partnerships.06 Dec 2011 Lungile Shoba-Zikhali 2
  3. 3. Formation of the TIA06 Dec 2011 Lungile Shoba-Zikhali 3
  4. 4. The Innovation chasm challenge OVERSEAS TECHNOLOGY SOURCES Research Development Production Large balance of payment IP Lost Innovation Local Industry Local Knowledge “Chasm” Research Development Manufacturing06 Dec 2011 Lungile Shoba-Zikhali 4
  5. 5. The innovation chasm- the strategic challenge continued COMMERCIALTHE INDUSTRIES ANDIDEAS, RESEARC MANUFACTURINGH ANDDEVELOPMENT 06 Dec 2011 Lungile Shoba-Zikhali 5 VALLEY OF DEATH
  7. 7. The TIA MandateMANDATE:“…to support the State in stimulating and intensifying technologicalinnovation in order to improve economic growth and the quality of lifeof all South Africans by „supporting & facilitating‟ the development andexploitation of technological innovations”The TIA Act [No 26 of 2008]06 Dec 2011 Lungile Shoba-Zikhali 7
  8. 8. TIA Funding Focus TIA geared towards addressing “market failure” and building bridges and institutional linkages along the innovation value chain: Private Equity High Risk/ Uncertain Return Low Risk/ High ReturnIP Value TIA Funding Focus Partnerships Partnerships (e.g. IDC, NEF) (e.g. NRF) PPP‟s CoCs Basic Research Applied Research Tech Development Manufacturing The TIA focuses its financial and non-financial offerings along the innovation chasm, and operates with the required flexibility across the innovation value chain through mobilising and leveraging national, regional and international partnerships 06 Dec 2011 Lungile Shoba-Zikhali 8
  9. 9. TIA Sectors TIA SECTORS Biotechnology Industrial Sectors Sectors Industrial AdvancedAgro Health Biotechnology Mining Energy Manufacturing ICT …Other … Fund Management; Expert Services; IP; Finance; PPM&E…06 Dec 2011 Lungile Shoba-Zikhali 9
  10. 10. Industrial Biotechnology (IB) INDUSTRIAL BIOTECHNOLOGY Source: definition:“the application of biotechnology for the environmentally friendlyproduction of products and processing of chemicals, pharmaceuticals,materials and bio-energy”. (OECD Workshop on “Outlook on Industrial Biotechnology”. Discussion paper –Session II “Industry Structure and Business Models for Industrial Biotechnology”. 13-15 Jan 2010)06 Dec 2011 Lungile Shoba-Zikhali 10
  11. 11. Industrial Biotechnology (IB)• Provides an opportunity to develop a sustainable, bio-based economy that uses eco-efficient bio-processes and renewable bio-resources.• Focuses on development of processes and production systems that: - save costs and are more profitable since they do not waste material -enable greater and more efficient utilization of renewable resources.• Products that are: -better performing, more durable and don’t persist after their useful life -less toxic, more easily recyclable and biodegradable -are derived from renewable resources -contribute minimally to net greenhouse gas emission06 Dec 2011 Lungile Shoba-Zikhali 11
  12. 12. Why Industrial Biotechnology? …Greening the SA economy for sustainable industrial development Drivers • Knowledge-based quality jobs …to achieve the „Triple Bottom Line‟ • Social responsibility Hurdles …3Ps of Sustainability • Unawareness • Acceptance SUSTAINABILITYDrivers• Cost reduction Drivers• Novel products • Less energyHurdles • Less waste• Regulations - i.e. Cleaner production• Further technology development Hurdles• Feedstock prices • Further technology development• Investments • Waste management06 Dec 2011 Lungile Shoba-Zikhali 12
  13. 13. Industrial Biotech Cross-Cutting Technology Sector06 Dec 2011 Lungile Shoba-Zikhali 13
  14. 14. Application of IBIB = cross-cutting „technology sector‟ e.g. Sectors where IB plays a roles Pharmaceutical…applies biotechnologies (microbial, plant and animal) for: Agriculture1. processing and Energy2. production of: Food & Beverage Chemicals (Bio) Chemicals Pulp & Paper (Bio) Materials Plastics (Bio) Energy Miningacross a diverse range of industry/economic sectors: Textiles 06 Dec 2011 Lungile Shoba-Zikhali 14
  15. 15. IB Value Chain06 Dec 2011 Lungile Shoba-Zikhali 15
  16. 16. IB Sub-Sector Focus Areas06 Dec 2011 Lungile Shoba-Zikhali 16
  17. 17. IB Sector Unit Objectives1. Stimulate and support the development of industrial biotechnology- based innovations for the environmentally friendly processing and production of chemicals, materials and energy2. Stimulate and support the development of industrial biotechnology- based private and/or public enterprises3. Leverage the TIA funds for co-investment into industrial biotechnology- based innovations06 Dec 2011 Lungile Shoba-Zikhali 17
  18. 18. IB Sector Unit Objectives4. Facilitate the development of human capital for technology innovation within industrial biotechnology investments to ensure sufficient firm and/or industry absorptive capacity* for new technologies5. Promote and support activities and events that facilitate the building of a culture of technology innovation and entrepreneurship*“ability to recognize the value of a new „technology‟, assimilate it, and apply it to commercial ends” Cohen and Levinthal(1990), "Absorptive capacity: A new perspective on learning and innovation", Administrative Science Quarterly, Volume 35, Issue 1 pg.128-152. 06 Dec 2011 Lungile Shoba-Zikhali 18
  19. 19. IB Sub-sectors1. BioChemicals: Products/processes with superior cost/performance ratio, e.g. enzymes in bioprocesses2. BioMaterials: Production of eco-efficient materials e.g. biodegradable3. BioEnergy: Technologies for efficient conversion of biomass feedstock for energy production4. BioRemediation: Technologies for effective & cost-efficient treatment and recycling of wastewater for improved water quality and reduced pollution/toxicity5. BioMinerals: Technologies for efficient & cost-effective bio-leaching/mining processes for extracting mineral resources 06 Dec 2011 Lungile Shoba-Zikhali 19
  20. 20. Expected Outcomes & Impact of IB Innovation in SA OUTCOMES IMPACT Increased application of biotechnology Enhanced competitiveness of industries1 in the process steps for the production of Eco-efficient use of the renewable raw chemicals and materials materials Increased use of renewable resources2 Sustainable industries less reliant on limited as raw materials for industrial applications Increased application of biotechnology fossil fuels3 in the manufacture of products across Economically & environmentally sustainable various industries manufacture of products Increased production of biomass- SA’s dependency on fossil fuels reduced4 derived energy based on biotechnology SA’s import of fuels reduced for everyday consumption Meaningful job creation Increased rural development that Improved standards of living for all SAs5 contributes to the supply of raw renewable materials Reduced waste generation Reduced production of greenhouse gases Increased cooperation, collaboration Increased contribution to the national GDP6 and support between researchers, Enhanced global competitiveness of South industry, government & civil society African firms & industries 06 Dec 2011 Lungile Shoba-Zikhali 20
  21. 21. Distribution by Focus Area 35 All Current 30 Completed 25 Pipeline 20 15 10 5 0 Biochemicals Biomaterials Bioenergy Bioremediation Other06 Dec 2011 Lungile Shoba-Zikhali 21
  22. 22. Examples of TIA IB Investments Production of anti-bodies in plant systems for the1. Rabivir Green Pharm development of therapeutics & diagnostics2. AzarGen Production of high value therapeutic peptides in plants Development & optimisation of a fermentation technology for3. FemTech the production of human recombinant proteins Development & optimization of a recombinant technology for4. Halodurans the production of therapeutic peptides.5. Enzyme Technologies Production of bromelain enzyme from pineapples Commercialisation of locally produced enzymes and6. ZA Biotech proprietary enzyme immobilisation technologies7. Lactase Enzyme Development of a fermentation bioprocess technology for(SLIEK) lactase production 06 Dec 2011 Lungile Shoba-Zikhali 22
  23. 23. Examples of TIA IB Investments Explore & characterize SA’s algal biodiversity and development8. Algal Bioprospecting a collection and database of algal strains for the production of biofuels Screening & classifying (database) fungi culture collections for9. Indigenous Fungi value adding products Validation of initial techno-economics of EPA/Omega 310. Algal Omega 3 production by SAs algal strains Validation of technology for fish waste beneficiation (omega 3 oil11. OM3 Oils extraction)12. Food and Cosmetic Development of novel formulation of low glycemic index sugarTechnologies Development of technology for the neutralisation of acid mine13. Acid Mine Drainage water and the biological removal of sulphate using sulphate 06 Dec 2011 reducing bacteriaShoba-Zikhali Lungile 23
  24. 24. Stage in the Innovation & Funding Value ChainPhase 1 Phase 2 Phase 3 Phase 4 Early Expansion Seed Start-up Expansion Technical Product & Business start Basic Idea Proof of development/ Business business up Research Generation Concept commercial growth development (tech based) planning AzarGen RabiVir Femtech Halodurans Enzyme ZA Biotech Technologies Lactase Enzyme (SLIEK) Algal Bioprospecting Indigenous Fungi Algal Food & Cosmetic Omega-3 OM3 Oils Technologies Acid Mine Drainage 06 Dec 2011 Lungile Shoba-Zikhali 24 DoE, NRF, DST TIA Support IDC , NEF
  25. 25. What the IB Sector Unit is looking for in Opportunities1. Technology Innovation opportunity – Science-based product/process/service offering with strong potential for market capitalisation2. Strong alignment with the TIA mandate, Corporate and Sector Strategic objectives3. Stage of technology development is beyond basic research (validated post-proof of concept)4. Potential for high socio-economic impact – addresses national imperatives e.g. job creation5. Strong potential to enhance industry competitiveness6. Presence of an industry commercialisation partner where relevant7. Co-Investment opportunity presented to allow risk-sharing06 Dec 2011 Lungile Shoba-Zikhali 25
  26. 26. Thank you Dec 2011 Lungile Shoba-Zikhali 26